Skip to content

Psych Capital PLC - Board Resignation, Role Change and Option Grant


Announcement provided by

Shortwave Life Sciences Plc · PSY

05/04/2024 14:00

Psych Capital PLC - Board Resignation, Role Change and Option Grant
RNS Number : 5454J
Psych Capital PLC
05 April 2024
 

5 April, 2024

PSYCH CAPITAL PLC

("Psych Capital", or "the Company")

William Potts Board Resignation and Role Change to Strategic Adviser

 

 Share Options Grant

London, UK, 5 April 2024 - Psych Capital Plc, an investment firm focused on innovative drug-development in the field of mental health, announces that William Potts, Chief Investment Officer, has stepped down from his role as a director of the Company. William Potts will remain as a Strategic Adviser of the Company. In his role as Strategic Adviser, William will assist with strategic opportunities for the Company.

William Potts commented: "It has been a pleasure to have worked with the exceptional team at Psych Capital over the years and I would like to thank them all for their hard work and dedication. I look forward to supporting Psych Capital during this exciting time to become a leader in Psychedelic science and healthcare."

Rivki Stern, Chief Executive Officer of the Company, stated: "William Potts has been instrumental in the building of Psych Capital and the implementation of its strategy and value proposition. We will continue to rely on William's strategic advice as we reaffirm our Company's commitment to supporting and developing pivotal treatments for mental health."

Grant of Share Options

 

The Company further announces that it has granted share options over ordinary shares of the Company, as part of the unapproved share option scheme, to its former chairman, Joseph Colliver, in recognition for the uncompensated work done by him leading up to the acquisition of Shortwave Pharma Inc,. The options grant was decided upon at the time of completion of the acquisition in November last year.

50,000 share options will be granted under the existing share option scheme with effect from 4 April 2024 and will be capable of being exercised for a period of 2 years. The exercise price is 2.95 pence per share, the mid-market share price on the day of issue, being April 4, 2024.

The directors of the Company accept responsibility for the contents of this announcement.

Enquiries:

Company:

Rivki Stern: +972 54 762 1621

 info@psych.capital

https://psych.capital

 

Peterhouse Capital Limited:

Corporate Adviser:
Guy Miller /Narisha Ragoonanthun: + 44 (0) 20 7469 0930

Corporate Broker

Lucy Williams: +44 (0) 20 7469 0930
Duncan Vasey: +44 (0) 20 7220 9797 (Direct)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXLELFBZZLLBBK]]>

View more ...

PSY announcementsAll announcements

Company

  • About
  • News
  • Investor Relations
  • Contact
  • Careers
ISO 27001 Certified

© Aquis Exchange 2024. All rights reserved.

Terms & ConditionsPrivacy PolicyModern Slavery & Human Trafficking Policy
System statusnormal